o2h ChaiTime Portfolio Pitch Day

About the event

The o2h ChaiTime Portfolio Pitch Day made its debut in February 2024, bringing fresh energy to our ChaiTime series with a brand-new in-person format at our Cambridge HQ.

The event was designed to do what o2h Ventures does best – spark collaboration, connect brilliant minds, and showcase breakthrough ideas in healthcare and biotech.

With a global audience dialling in via Zoom and a curated group of investors and strategic partners in the room, the afternoon buzzed with live pitches, questions, and future-shaping conversations.

We were thrilled to spotlight six pioneering portfolio companies pushing the boundaries of science and medicine:

Dr Catherine Beech, CEO at Exonate

Jeff Roix, Venture Partner at Neurocentrx
Dr Arpan Desai, CEO at CamGene Tx
Dr Thomas Mcnally, CSO at Alevin Tx
Dr Marcus Yeo, CEO at Ascend Bio
Dr Hannah Sore, CEO at PharmEnable

Keynote Speaker:
Dr Harren Jhoti, President and CEO at Astex Pharmaceuticals

The first edition set the tone for what ChaiTime Portfolio Pitch Day is all about – ideas worth backing, conversations worth having, and a community worth building.

02-02-2024

14.30 to 16.30 GMT

o2h Ventures Limited, Hauxton House, Cambridge + Web Streaming (Zoom)

Register for future events

Related events

February 2026 Edition

in-person organising

5th February, 2026

o2h ChaiTime - London February 2026 Edition

Join us for the first in-person o2h ChaiTime, hosted in collaboration with J.P. Morgan in London.

January 2026 Edition

in-person organising

23rd January, 2026

o2h ChaiTime Portfolio Pitch Day - Fund Launch Series - Jan 2026 Edition

Join a curated mix of investors, founders, and ecosystem leaders to build new collaborations in a relaxed, down-to-earth setting. Be part of the first event kicking off our Growth Fund Launch Series.

Watch now

EISA 2025

attending in-person

6th November, 2025

Ready Steady Grow - Cambridge 2025

We were delighted to participate in EISA’s Ready, Steady, Grow event in Cambridge, where Chris White joined the panel to share insights on supporting early-stage biotech innovation.

Discover more

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)